Author | Deana Ferreri, PhD


Faster Drug Approvals, Weaker Data? Study Raises Questions About FDA Process

February 21, 2020

Special approval programs have increased FDA administrative costs (paid for mostly by user fees), and postponements of generic competition have been costly to the US healthcare system, according to a recent article in JAMA.